Results 31 to 40 of about 2,327,860 (219)
Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice [PDF]
, 2013 Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH).
Emiri Mandeville +58 more
core +2 more sources
Journal of Medical Case Reports, 2019 Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous
Toshiyuki Ohtani +3 more
doaj +1 more source
Interdisciplinary Neurosurgery, 2023 Intravenous recombination of tissue plasminogen activator is a recommended treatment for patients with ischemic stroke. However, its side effects are associated with an increased risk of intracerebral hemorrhage.
Waitayaporn Pengtong +2 more
doaj +1 more source
Treatment of infective endocarditis with recombinant tissue plasminogen activator [PDF]
Pediatric Blood & Cancer, 2007 AbstractInfective endocarditis (IE) caused by microbial infection is virtually always fatal if untreated. High‐dose and long‐term antibiotic treatment is required to eradicate microorganisms. If increased risk of embolic events, persistent infection, and progressive cardiac failure are present, surgery is indicated.
Bostan, ÖZLEM MEHTAP +3 more
openaire +3 more sources
Acute stroke thrombolysis in infective endocarditis
SAGE Open Medical Case Reports, 2018 Intravenous recombinant tissue plasminogen activator is not recommended for the treatment of acute ischemic stroke in patients with infective endocarditis due to the risk of hemorrhagic transformation of septic emboli and few reported cases in the ...
Abdulaziz Ashkanani +2 more
doaj +1 more source
Activation of the complement system by recombinant tissue plasminogen activator
Journal of the American College of Cardiology, 1987 Recent trials have shown that recombinant tissue plasminogen activator (rt-PA) is an effective thrombolytic agent in patients with acute myocardial infarction. Because rt-PA converts plasminogen to plasmin, which is known to activate complement in vitro, we tested the hypothesis that rt-PA can induce in vivo activation of complement.
Bennett, William R. +7 more
openaire +2 more sources
Phlegmasia cerulea dolens secondary to an aortoiliac aneurysm
Journal of Vascular Surgery Cases and Innovative Techniques, 2019 Phlegmasia cerulea dolens is an uncommon entity. We present a case of phlegmasia cerulea dolens secondary to an aortoiliac aneurysm that compressed the common iliac vein.
Morten Vetrhus, MD, PhD +3 more
doaj +1 more source
The Desmoteplase In Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase [PDF]
, 2005 <p><b>Background and Purpose:</b> Most acute ischemic stroke patients arrive after the 3-hour time window for recombinant tissue plasminogen activator (rtPA) administration.
Fischer, M. +21 more
core +1 more source
Journal of Biological Chemistry, 1984 The kinetics of the activation of plasminogen by tissue-type plasminogen activator were studied in the presence and the absence of CNBr-digested fibrinogen as a soluble cofactor. Michaelis-Menten kinetics applied and the kinetic parameters obtained were very similar to those previously reported for the activation in the presence of solid phase fibrin ...
C, Zamarron, H R, Lijnen, D, Collen
openaire +2 more sources
Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation [PDF]
, 2010 <p><b>Background and Purpose:</b> Mechanisms of early neurologic deterioration after treatment with intravenous, recombinant, tissue-type plasminogen activator (IV rt-PA) include symptomatic intracerebral hemorrhage (SICH) and early ...
Tracey Baird +11 more
core +1 more source